Advertisement

Abstract

Over 10 million people have osteoporosis, 34 million have low bone mineral density (BMD), and over 1.5 million osteoporosis-related fractures occur each year in the United States alone (1). The 2002 year direct medical costs for osteoporotic fractures exceeded $18 billion in the United States (2).

Keywords

Bone Mineral Density Bone Loss Bone Mass Vertebral Fracture Fracture Risk 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

References

  1. 1.
    National Osteoporosis Foundation. Fast facts on osteo-porosis. Available at: http://www.nof.org/osteoporosis/diseasefacts.htm. Accessed July 2, 2007.
  2. 2.
    National Osteoporosis Foundation. Physician’s guide to prevention and treatment of osteoporosis. Belle Mead, NJ: Excerpta Medica; 1998.Google Scholar
  3. 3.
    Melton III LJ, Chrischilles EA. How many women have osteoporosis? J Bone Miner Res 1992;7:1005–1010.CrossRefPubMedGoogle Scholar
  4. 4.
    Chrischilles EA, et al. A model of lifetime osteoporosis impact. Arch Intern Med 1991;151: 2026–2032.CrossRefPubMedGoogle Scholar
  5. 5.
    Cummings SR, Black DM, Rubin SM. Lifetime risks of hip, Colles’, or vertebral fracture and coronary heart disease among white postmenopausal women. Arch Intern Med 1989;149:2445–2448.Google Scholar
  6. 6.
    National Osteoporosis Foundation. Osteoporosis: review of the evidence for prevention, diagnosis, and treatment and cost-effectiveness analysis. Status report. Osteoporos Int 1998;8(Suppl 4):S1–S88.Google Scholar
  7. 7.
    Popovic JR. 1999 National Hospital Discharge Survey: annual summary with detailed diagnosis and procedure data. Vital Health Stat 2001;13:i–v, 1–206.Google Scholar
  8. 8.
    Cooper C, Campion G, Melton LJ III. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992;2:285–289.CrossRefPubMedGoogle Scholar
  9. 9.
    Farmer ME, et al. Race and sex differences in hip fracture incidence. Am J Public Health 1984;74:1374–1830.CrossRefPubMedGoogle Scholar
  10. 10.
    Sugarman JR, et al. Hip fracture incidence in nursing home residents and community-dwelling older people, Washington State, 1993–1995. J Am Geriatr Soc 2002;50:1638–1643.CrossRefPubMedGoogle Scholar
  11. 11.
    Johnell O. The socioeconomic burden of fractures: today and in the 21st century. Am J Med 1997;103:20S–25S, discussion 25S–26S.CrossRefPubMedGoogle Scholar
  12. 12.
    Ross PD. Osteoporosis: frequency, consequences, and risk factors. Arch Intern Med 1996;156:1399–1411.CrossRefPubMedGoogle Scholar
  13. 13.
    Looker AC, et al. Prevalence of low femoral bone density in older US adults from NHANES III. J Bone Miner Res 1997;12:1761–1768.CrossRefPubMedGoogle Scholar
  14. 14.
    Green AD, et al. Does this woman have osteoporosis? JAMA 2004;292:2890–2900.CrossRefPubMedGoogle Scholar
  15. 15.
    Genant HK, et al. Vertebral fracture assessment using a semiquantitative technique. J Bone Miner Res 1993;8:1137–1148.CrossRefPubMedGoogle Scholar
  16. 16.
    Watts NB. Fundamentals and pitfalls of bone densitometry using dual-energy X-ray absorptiometry (DXA). Osteoporos Int 2004;15:847–854.CrossRefPubMedGoogle Scholar
  17. 17.
    Nelson HD, et al. Osteoporosis and fractures in postmenopausal women using estrogen. Arch Intern Med 2002;162:2278–2284.CrossRefPubMedGoogle Scholar
  18. 18.
    International Society for Clinical Densitometry (ISCD). Official positions of the ISCD. J Clin Densitom 2002;5(Suppl).Google Scholar
  19. 1.
    Boyle WJ, Scott Simonet W, Lacey DL. Osteoclast differentiation and activation. Nature 2003;423:337–342.CrossRefPubMedGoogle Scholar
  20. 2.
    Cenci S, Weitzmann MN, Roggia C, et al. Estrogen deficiency induces bone loss by enhancing T-cell production of TNF-alpha. J Clin Invest 2000;106:1229–1237.CrossRefPubMedGoogle Scholar
  21. 3.
    Pfeilschifter J, Koditz R, Pfohl M, Schatz H. Changes in proinflammatory cytokine activity after menopause. Endocr Rev 2002;23:90–119.CrossRefPubMedGoogle Scholar
  22. 4.
    Currey JD. The mechanical properties of bone. In: Currey JD, ed. Bones: structure and mechanics. 2nd ed. Princeton, NJ: Princeton University Press; 2002:54–122.Google Scholar
  23. 5.
    Naganathan V, MacGregor A, Snieder H, Nguyen T, Spector T, Sambrook PN. Gender differences in the genetic factors responsible for variation in bone density and ultrasound. J Bone Miner Res 2002;17:725–733.CrossRefPubMedGoogle Scholar
  24. 6.
    Mann V, Hobson EE, Li B, et al. A COL1A1 Sp1 binding site polymorphism predisposes to osteoporotic fracture by affecting bone density and quality. J Clin Invest 2001;107:899–907.CrossRefPubMedGoogle Scholar
  25. 7.
    Van Staa TP, Leufkens HGM, Abenhaim L, Zhang B, Cooper C. Use of oral glucocorticoids and risk of fractures. J Bone Miner Res 2000;15:993–1000.CrossRefPubMedGoogle Scholar
  26. 8.
    Petty S, Paton LM, O’Brien TJ, et al. Effect of antiepileptic medication on bone mineral measures. Neurology 2005;65:1358–1365.CrossRefPubMedGoogle Scholar
  27. 9.
    Gage BF, Birman-Deych E, Radford, MJ, Nilasena, DS, Binder EF. Risk of osteoporotic fracture in elderly patients taking warfarin: results from the national registry of Atrial Fibrillation 2. Arch Intern Med 2006;166:241–246.CrossRefPubMedGoogle Scholar
  28. 10.
    Eastell R, Hannon R. Long term effects of aromatase inhibitors on bone. J Steroid Biochem Molec Biol 2005;95:151–154.CrossRefPubMedGoogle Scholar
  29. 1.
    Holick MF, Siris ES, Binkley N, et al. Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215–3224.CrossRefPubMedGoogle Scholar
  30. 2.
    Reginster J-Y, Minne HW, Sorensen OH, et al. Ran-domized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000;11:83–91.CrossRefPubMedGoogle Scholar
  31. 3.
    Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 1996;348:1535–1541.CrossRefPubMedGoogle Scholar
  32. 4.
    Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis—a randomized controlled trial. JAMA 1999;282:1344–1352.CrossRefPubMedGoogle Scholar
  33. 5.
    McClung MR, Geusens P, Miller PD, et al. Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 2001;344:333–340.CrossRefPubMedGoogle Scholar
  34. 6.
    Chesnut CH III, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004;19:1241–1249.CrossRefGoogle Scholar
  35. 7.
    Reid IR, Brown JP, Burckhardt P, et al. Intravenous zoledronic acid in postmenopausal women with low bone mineral density. N Engl J Med 2002;346:653–661.CrossRefPubMedGoogle Scholar
  36. 8.
    Chesnut CH III, Silverman S, Andriano K, et al. A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the Prevent Recurrence of Osteoporotic Fractures study. Am J Med 2000;102:267–276.CrossRefGoogle Scholar
  37. 9.
    Writing Group for the Women’s Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002;288:321–333.CrossRefGoogle Scholar
  38. 10.
    Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene—results from a 3-year randomized clinical trial. JAMA 1999;282:637–645.CrossRefPubMedGoogle Scholar
  39. 11.
    Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001;344:1434–1441.CrossRefPubMedGoogle Scholar
  40. 12.
    Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 2003;349:1207–1215.CrossRefPubMedGoogle Scholar
  41. 13.
    Cosman F, Nieves J, Zion M, Woelfert L, Luckey M, Lindsay R. Daily and cyclic parathyroid hormone in women receiving alendronate. N Engl J Med 2005;353:566–575.CrossRefPubMedGoogle Scholar
  42. 14.
    Black DM, Bilezikian JP, Ensrud KE, et al. One year of alendronate after one year of parathyroid hormone (1–84) for osteoporosis. N Engl J Med 2005;353:555–565.CrossRefPubMedGoogle Scholar
  43. 15.
    Meunier PJ, Roux C, Seeman E, et al. The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004;350:459–468.CrossRefPubMedGoogle Scholar
  44. 16.
    Reginster J-Y, Seeman E, De Vernejoul M-C, et al. Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: treatment of Peripheral Osteoporosis (TROPOS) Study. J Clin Endocrinol Metab 2005;90:2816–2822.CrossRefPubMedGoogle Scholar
  45. 17.
    McClung MR, Lewiecki EM, Cohen SB, et al. Denosumab in postmenopausal women with low bone mineral density. N Engl J Med 2006;354:821–831.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2008

Authors and Affiliations

  • Kenneth G. Saag
    • 1
  1. 1.Division of Clinical Immunology and RheumatologyUniversity of Alabama at BirminghamBirminghamUSA

Personalised recommendations